{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-029851","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.215747+00:00","generated_at":"2026-06-13T17:10:23.406429+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Adicet Bio ADI-001 Phase 1 shows 71% ORR; pivots to Phase 2 in 1H24","bullets":["ADI-001 achieved 71% ORR & 63% CR across doses in heavily pre-treated NHL (median 4 prior lines; 50% post-CAR T).","At RP2D (1B cells), CR rate 63%, 6-month CR rate 25%; in post-CAR T patients CR rate 67% (6-month CR 33%).","No GvHD; only 1 Grade 3+ CRS and 1 Grade 3+ ICANS among 24 safety-evaluable patients.","FDA Type B meeting completed; plan to start potentially pivotal Phase 2 in post-CAR T LBCL in 1H 2024.","ADI-001 persistence at RP2D (Cmax 483 cells/µL day 9) exceeded approved autologous CD19 CAR T."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-029851","json":"https://secwatch.observer/filing/0000950170-23-029851.json","markdown":"https://secwatch.observer/filing/0000950170-23-029851.md","text":"https://secwatch.observer/filing/0000950170-23-029851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023029851/0000950170-23-029851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017023029851/acet-20230626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:10:23.406429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}